Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs.
Molecular cancer therapeutics (2012) - Comments
doi: 10.1158/1535-7163.MCT-11-0814  pubmed: 22532603  pmc: PMC3374071 

Ali R. Jazirehi, James S. Economou